{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:13Z","timestamp":1791357373170,"version":"4.3.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.biopha.2021.112295","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T11:01:18Z","timestamp":1641034878000},"page":"112295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A retrospective analysis of the \u201cNeverending Trip\u201d after administration of a potent full agonist of 5-HT2A receptor \u2013 25I-NBOMe"],"prefix":"10.1016","volume":"146","author":[{"given":"Daria","family":"Schetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Schetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Koci\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112295_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnins.2020.00078","article-title":"NBOMes-highly potent and toxic alternatives of LSD","volume":"14","author":"Zawilska","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2021.112295_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13722-015-0024-7","article-title":"Designer drugs 2015: assessment and management","volume":"10","author":"Weaver","year":"2015","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.biopha.2021.112295_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psym.2018.11.002","article-title":"Clinical and toxicological profile of NBOMes: a systematic review","volume":"60","author":"Marchi","year":"2019","journal-title":"Psychosomatics"},{"issue":"9","key":"10.1016\/j.biopha.2021.112295_bib4","first-page":"506","article-title":"Hallucinogen Persisting Perception Disorder (HPPD) and flashback phenomena \u2013 differential diagnosis and explanation models","volume":"83","author":"Hermle","year":"2015","journal-title":"Fortschr. Neurol. Psychiatr."},{"issue":"47","key":"10.1016\/j.biopha.2021.112295_bib5","first-page":"1","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","volume":"8","author":"Martinotti","year":"2018","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.biopha.2021.112295_bib6","first-page":"67","article-title":"LSD-associated \u201cAlice in Wonderland Syndrome\u201d(AIWS): a Hallucinogen Persisting Perception Disorder (HPPD) case report","volume":"52","author":"G Lerner","year":"2015","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"10.1016\/j.biopha.2021.112295_bib7","series-title":"Diagnostic and Statistical Manual of Mental Disorders\u2013\u2013Fifth Version","article-title":"DSM 5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.biopha.2021.112295_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.09.030","article-title":"Next generation of novel psychoactive substances on the horizon - a complex problem to face","volume":"157","author":"Zawilska","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"10.1016\/j.biopha.2021.112295_bib9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00063-018-0405-2","article-title":"Bonzai, lead and bath salt-poisoning with new and old drugs: synthetic amphetamines, cathinones, cannabinoids and opioids-an overview","volume":"114","author":"Strube","year":"2019","journal-title":"Med Klin. Intensiv. Notfmed."},{"key":"10.1016\/j.biopha.2021.112295_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1192\/bjp.100.419.491","article-title":"The therapeutic value of lysergic acid diethylamide in mental illness","volume":"100","author":"Sandison","year":"1954","journal-title":"J. Ment. Sci."},{"key":"10.1016\/j.biopha.2021.112295_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fpsyt.2017.00240","article-title":"The \u201cEndless Trip\u201d among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review","volume":"8","author":"Orsolini","year":"2017","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.biopha.2021.112295_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1192\/bjp.140.5.518","article-title":"A chronic impairment of colour vision in users of LSD","volume":"140","author":"Abraham","year":"1982","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.biopha.2021.112295_bib13","series-title":"Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/7854_2016_457","article-title":"A review of Hallucinogen Persisting Perception Disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD","author":"Halpern","year":"2016"},{"issue":"5","key":"10.1016\/j.biopha.2021.112295_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0361-9230(01)00623-2","article-title":"Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists","volume":"56","author":"Gray","year":"2001","journal-title":"Brain Res. Bull."},{"issue":"3","key":"10.1016\/j.biopha.2021.112295_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1017\/S1461145705005055","article-title":"Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei","volume":"8","author":"Adams","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112295_bib16","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1176\/ajp.2006.163.5.934","article-title":"Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger\u2019s syndrome: an in vivo SPECT study","volume":"163","author":"Murphy","year":"2006","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.biopha.2021.112295_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neulet.2004.12.059","article-title":"5-HT2A and muscarinic receptors in schizophrenia: a postmortem study","volume":"379","author":"Matsumoto","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2021.112295_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200767010-00004","article-title":"Serotonergic drugs: effects on appetite expression and use for the treatment of obesity","volume":"67","author":"Halford","year":"2007","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.biopha.2021.112295_bib19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/FBP.0b013e328345f90d","article-title":"Serotonin (5-hydroxytryptamine) 5-HT(2A) receptor: association with inherent and cocaine-evoked behavioral disinhibition in rats","volume":"22","author":"Anastasio","year":"2011","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.biopha.2021.112295_bib20","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2021.112295_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fphar.2018.00017","article-title":"Tolerance and tachyphylaxis to head twitches induced by the 5-HT2A agonist 25CN-NBOH in mice","volume":"9","author":"Buchborn","year":"2018","journal-title":"Front Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112295_bib22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2021.112295_bib23","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1983.01790070074009","article-title":"Visual phenomenology of the LSD flashback","volume":"40","author":"Abraham","year":"1983","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2021.112295_bib24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.biopha.2021.112295_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0925-4927(01)00098-1","article-title":"EEG coherence in post-LSD visual hallucinations","volume":"107","author":"Abraham","year":"2001","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.biopha.2021.112295_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","article-title":"Hallucinogen persisting perception disorder: what do we know after 50 years?","volume":"69","author":"Halpern","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.biopha.2021.112295_bib27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0269881120919957","article-title":"Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis","volume":"34","author":"Romeo","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.biopha.2021.112295_bib28","series-title":"Depression: How Effective Are Antidepressants?","author":"InformedHealth.org","year":"2017"},{"issue":"6","key":"10.1016\/j.biopha.2021.112295_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2021.112295_bib30","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1038\/sj.npp.1395318","article-title":"Serotonin and hallucinogens","volume":"21","author":"Aghajanian","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2021.112295_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0022-3476(06)80189-7","article-title":"LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents","volume":"125","author":"Markel","year":"1994","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.biopha.2021.112295_bib32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JCP.0000000000000869","article-title":"Resolution of acute-onset depersonalization\/derealization with clonazepam and inpatient hospitalization","volume":"38","author":"Weber","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112295_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/14737175.8.1.19","article-title":"Depersonalization disorder: pharmacological approaches","volume":"8","author":"Sierra","year":"2008","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/j.biopha.2021.112295_bib34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","article-title":"Benzodiazepine harm: how can it be reduced?","volume":"77","author":"Lader","year":"2014","journal-title":"Br. J. Clin. Pharm."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221010799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221010799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:46:23Z","timestamp":1779965183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221010799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":34,"alternative-id":["S0753332221010799"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112295","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective analysis of the \u201cNeverending Trip\u201d after administration of a potent full agonist of 5-HT2A receptor \u2013 25I-NBOMe","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112295"}}